Nanobiotix S.A. (NBTX) stock
NBTXNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as NNBXF
$26.90−0.55 (-2.00%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Nanobiotix operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2025 it was -€10.82M. The highest annual figure on record is -€10.82M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -€10.82M | – |
| FY2024 | Dec 31, 2024 | -€68.39M | – |
| FY2023 | Dec 31, 2023 | -€26.78M | – |
| FY2022 | Dec 31, 2022 | -€46.70M | – |
| FY2021 | Dec 31, 2021 | -€52.58M | – |
| FY2020 | Dec 31, 2020 | -€36.43M | – |
| FY2019 | Dec 31, 2019 | -€46.78M | – |
| FY2018 | Dec 31, 2018 | -€30.07M | – |
See a number that looks wrong?